136 related articles for article (PubMed ID: 29724879)
1. Unit-Dose Packaging and Unintentional Buprenorphine-Naloxone Exposures.
Wang GS; Severtson SG; Bau GE; Dart RC; Green JL
Pediatrics; 2018 Jun; 141(6):. PubMed ID: 29724879
[TBL] [Abstract][Full Text] [Related]
2. The Role of Unit-Dose Child-Resistant Packaging in Unintentional Childhood Exposures to Buprenorphine-Naloxone Tablets.
Hampp C; Lovegrove MC; Budnitz DS; Mathew J; Ho A; McAninch J
Drug Saf; 2020 Feb; 43(2):189-191. PubMed ID: 31745829
[No Abstract] [Full Text] [Related]
3. Root causes, clinical effects, and outcomes of unintentional exposures to buprenorphine by young children.
Lavonas EJ; Banner W; Bradt P; Bucher-Bartelson B; Brown KR; Rajan P; Murrelle L; Dart RC; Green JL
J Pediatr; 2013 Nov; 163(5):1377-83.e1-3. PubMed ID: 23993129
[TBL] [Abstract][Full Text] [Related]
4. Buprenorphine Exposures Among Children and Adolescents Reported to US Poison Control Centers.
Post S; Spiller HA; Casavant MJ; Chounthirath T; Smith GA
Pediatrics; 2018 Jul; 142(1):. PubMed ID: 29941678
[TBL] [Abstract][Full Text] [Related]
5. Clinical effects of unintentional pediatric buprenorphine exposures: experience at a single tertiary care center.
Toce MS; Burns MM; O'Donnell KA
Clin Toxicol (Phila); 2017 Jan; 55(1):12-17. PubMed ID: 27756148
[TBL] [Abstract][Full Text] [Related]
6. Understanding abuse of buprenorphine/naloxone film versus tablet products using data from ASI-MV® substance use disorder treatment centers and RADARS® System Poison Centers.
Butler SF; Black RA; Severtson SG; Dart RC; Green JL
J Subst Abuse Treat; 2018 Jan; 84():42-49. PubMed ID: 29195592
[TBL] [Abstract][Full Text] [Related]
7. Toddlers requiring pediatric intensive care unit admission following at-home exposure to buprenorphine/naloxone.
Pedapati EV; Bateman ST
Pediatr Crit Care Med; 2011 Mar; 12(2):e102-7. PubMed ID: 20921918
[TBL] [Abstract][Full Text] [Related]
8. Buprenorphine prescribing practices and exposures reported to a poison center--Utah, 2002-2011.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(49):997-1001. PubMed ID: 23235296
[TBL] [Abstract][Full Text] [Related]
9. Decline in Buprenorphine/Naloxone Prescriptions in a State Medicaid Population Following Formulary Conversion from Suboxone to Bunavail.
Soper R; Appajosyula S; Deximo C
Adv Ther; 2018 Apr; 35(4):457-466. PubMed ID: 29623562
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology of pediatric buprenorphine and methadone exposures reported to the poison centers.
Rege SV; Ngo DA; Ait-Daoud N; Rizer J; Sharma S; Holstege CP
Ann Epidemiol; 2020 Feb; 42():50-57.e2. PubMed ID: 31992493
[TBL] [Abstract][Full Text] [Related]
11. Respiratory depression following medications for opioid use disorder (MOUD)-approved buprenorphine product oral exposures; National Poison Database System 2003-2019.
Darracq MA; Thornton SL
Clin Toxicol (Phila); 2021 Apr; 59(4):303-312. PubMed ID: 32894033
[TBL] [Abstract][Full Text] [Related]
12. Notes from the Field: Pediatric Emergency Department Visits for Buprenorphine/Naloxone Ingestion - United States, 2008-2015.
Budnitz DS; Lovegrove MC; Sapiano MR; Mathew J; Kegler SR; Geller AI; Hampp C
MMWR Morb Mortal Wkly Rep; 2016 Oct; 65(41):1148-1149. PubMed ID: 27764078
[TBL] [Abstract][Full Text] [Related]
13. Association between buprenorphine/naloxone and high-dose opioid analgesic prescribing in Kentucky, 2012-2017.
Luu H; Slavova S; Freeman PR; Lofwall M; Browning S; Slade E; Bush H
Drug Alcohol Depend; 2019 Dec; 205():107606. PubMed ID: 31606590
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a Food and Drug Administration Mandate to Limit Acetaminophen in Prescription Combination Products.
Goldberger D; Vearrier D
J Med Toxicol; 2017 Dec; 13(4):303-308. PubMed ID: 28710607
[TBL] [Abstract][Full Text] [Related]
15. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
[TBL] [Abstract][Full Text] [Related]
16. Unintentional methadone and buprenorphine exposures in children: Developing prevention messages.
Schwartz L; Mercurio-Zappala M; Howland MA; Hoffman RS; Su MK
J Am Pharm Assoc (2003); 2017; 57(2S):S83-S86. PubMed ID: 28292505
[TBL] [Abstract][Full Text] [Related]
17. Frequency of Poison Center Exposures for Pediatric Accidental Unsupervised Ingestions of Acetaminophen after the Introduction of Flow Restrictors.
Brass EP; Reynolds KM; Burnham RI; Green JL
J Pediatr; 2018 Jul; 198():254-259.e1. PubMed ID: 29622340
[TBL] [Abstract][Full Text] [Related]
18. The impact of the prescription opioid epidemic on young children: Trends and mortality.
Wang GS; Olsen H; Severtson G; Green JL; Dart RC
Drug Alcohol Depend; 2020 Jun; 211():107924. PubMed ID: 32178937
[TBL] [Abstract][Full Text] [Related]
19. Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.
Walsh SL; Nuzzo PA; Babalonis S; Casselton V; Lofwall MR
Drug Alcohol Depend; 2016 May; 162():190-8. PubMed ID: 27012435
[TBL] [Abstract][Full Text] [Related]
20. Flow Restrictors and Reduction of Accidental Ingestions of Over-the-Counter Medications.
Paul IM; Reynolds KM; Delva-Clark H; Burnham RI; Green JL
Am J Prev Med; 2019 Jun; 56(6):e205-e213. PubMed ID: 31003808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
